Peptide Initiative

Peptide history · 1983

Liraglutide (Victoza / Saxenda)

The Anglerfish Discovery That Launched the Weight-Loss Revolution

FDA Approved1902 – 2024

From a deep-sea fish to the world's medicine cabinets — follow the 40-year journey of a gut hormone that nobody believed in, a scientist who refused to quit, and the drug that changed how we treat diabetes and obesity forever.

1983GLP-1 Discovery

Found hidden inside the glucagon gene

2010 / 2014FDA Approval

Victoza for diabetes, Saxenda for weight loss

31Amino Acids

97% identical to natural GLP-1

13 hoursHalf-Life

Up from just 2 minutes for natural GLP-1

3,751 DaMolecular Weight

Daltons

2024Lasker Award

Awarded to the three GLP-1 pioneers

  • Dr. Joel Habener

    The Gene Hunter · Massachusetts General Hospital / Harvard

    In the early 1980s, Habener was studying anglerfish — deep-sea fish with huge pancreases — when he found something unexpected hiding in the glucagon gene: a second hormone that would turn out to be GLP-1. This accidental find launched the entire field of incretin medicine.

    The eureka moment was when we discovered that inside the larger glucagon protein, there was a second peptide we hadn't expected — one that would change medicine forever.
  • Dr. Svetlana Mojsov

    The Chemist Who Cracked the Code · The Rockefeller University

    Mojsov figured out that GLP-1 needed to be cut at just the right spot to become active. She made the active form by hand in her lab, proved it could trigger insulin release, and showed it was produced in the gut — not the pancreas. Her 1987 paper is considered the birth certificate of GLP-1 medicine.

    I made antibodies, I synthesized the peptide, I did the experiments. It was clear this was the incretin hormone people had been searching for since the 1960s.
  • Lotte Bjerre Knudsen

    The Unstoppable Champion · Novo Nordisk

    For over 20 years at Novo Nordisk, Knudsen fought against internal skeptics to develop GLP-1 drugs. When colleagues wanted to abandon the project, she kept going. Her team invented the fatty acid trick that turned a 2-minute hormone into a 13-hour drug — creating liraglutide.

    So many people at Novo Nordisk did not believe in GLP-1. I could have given up several times when it was just tough to keep going. But I knew this science was real.
  • Dr. Jens Juul Holst

    The Clinical Visionary · University of Copenhagen

    While other scientists showed that a similar gut hormone called GIP stopped working in diabetic patients, Holst proved that GLP-1 still worked perfectly. This was the green light the field needed — GLP-1 could actually help real patients with real diabetes.

    Everyone was disappointed when GIP failed in diabetic patients. But when we tested GLP-1, the insulin response was beautiful — it worked exactly as it should.

  1. The Discovery

    A Hidden Epidemic

    The World Before GLP-1

    Key moment

    Fen-phen pulled from market after heart damage in thousands

    By the 1980s, type 2 diabetes was becoming a crisis. Rates were climbing every year, and the treatments were limited and often dangerous. Insulin injections could cause blood sugar to crash dangerously low. Other pills had harsh side effects and often stopped working after a few years.

    Obesity was even harder to treat. Doctors had almost nothing to offer. Diet pills from the 1960s and 70s — amphetamines — turned out to be addictive. The combination drug fen-phen, introduced in the 1990s, would later be pulled from shelves after causing heart valve damage in thousands of patients. For millions of people struggling with their weight, medicine had failed them.

    Scientists had known since the 1960s that something in the gut helped control blood sugar. When you eat food, your intestines release chemical signals that tell the pancreas to make insulin. Researchers called this the 'incretin effect.' But nobody could figure out which chemical was doing the heavy lifting — or how to turn it into a medicine.

  2. The Breakthrough

    The Anglerfish Secret

    A Discovery Nobody Expected

    Key moment

    GLP-1 triggered a 6-fold surge in insulin at natural blood levels

    Joel Habener at Massachusetts General Hospital was studying anglerfish — bizarre deep-sea creatures with oversized pancreases that made them perfect for hormone research. When his team read the genetic code of the glucagon gene, they found something hidden inside: the blueprint for a second, unknown hormone. They called it glucagon-like peptide-1, or GLP-1.

    But finding the gene was only half the battle. In a nearby lab, a chemist named Svetlana Mojsov realized that the full-length GLP-1 protein was useless — it had to be trimmed to a shorter, 31-amino-acid version to become active. She built the active form by hand, one amino acid at a time, in her chemistry lab.

    In early 1987, Mojsov, Habener, and physician Gordon Weir tested her hand-built peptide on isolated rat pancreases. The result was stunning: at incredibly tiny concentrations — levels naturally found in the bloodstream — GLP-1 triggered a six-fold surge in insulin production. They had found the missing incretin hormone that scientists had been hunting for over 20 years.

  3. The Trials

    The Two-Minute Problem

    A Brilliant Molecule With a Fatal Flaw

    Key moment

    Half-life extended from 2 minutes to 13 hours

    There was a catch that nearly killed the entire project. Natural GLP-1 disappears from the blood in less than two minutes. An enzyme called DPP-4 chews it apart almost instantly. Injecting pure GLP-1 into patients was like pouring water into a bucket full of holes — it drained away before it could do any good.

    At Novo Nordisk in Denmark, a young scientist named Lotte Bjerre Knudsen believed she could solve this problem. Her idea was simple but clever: attach a fatty acid — a small chain of fat molecules — to GLP-1. This fatty chain would grab onto albumin, a large protein that floats through the bloodstream like a cargo ship. By hitching a ride on albumin, the tiny GLP-1 molecule would be shielded from the enzymes trying to destroy it.

    Knudsen's team tested hundreds of combinations — different fat chains attached at different spots on the peptide. Most failed. But one version stood out: a 16-carbon fatty acid chain attached at position 26, with one amino acid swapped from lysine to arginine at position 34. This molecule — liraglutide — lasted 13 hours in the body. The two-minute hormone had become a once-daily drug.

  4. The Crisis

    The Storm of Doubt

    Cancer Fears and Corporate Pressure

    Key moment

    Public Citizen demanded FDA pull Victoza from market

    As liraglutide moved through clinical trials, trouble arrived. In rodent studies, the drug caused thyroid tumors in rats and mice. The FDA slapped a black box warning — the most serious kind — on the label. Headlines screamed about cancer risks. In 2012, the consumer advocacy group Public Citizen demanded that the FDA pull Victoza from the market entirely, arguing the cancer and pancreatitis risks outweighed the benefits.

    Inside Novo Nordisk, skeptics who had always doubted GLP-1 felt vindicated. Why keep pushing a drug with a cancer warning? But Knudsen and her allies pointed out a crucial detail: the thyroid tumors appeared only in rodents, not humans. Rats have a specific receptor in their thyroid cells that humans barely have. The rodent data, they argued, was a false alarm.

    Meanwhile, pancreatitis cases surfaced in some patients. The FDA launched investigations. Competitors circled. For several tense years, liraglutide's future hung in the balance. Novo Nordisk bet everything on a massive cardiovascular safety trial called LEADER — enrolling over 9,000 patients across 32 countries — to prove once and for all that liraglutide was not just safe, but beneficial.

  5. The Legacy

    The Revolution Arrives

    From Diabetes Drug to Weight-Loss Breakthrough

    Key moment

    LEADER showed 13% reduction in cardiovascular death

    The LEADER trial results, published in 2016, were a turning point. Not only was liraglutide safe — it actually reduced the risk of heart attacks, strokes, and death from heart disease by 13%. The drug that critics wanted banned was now saving lives.

    But the biggest surprise had been hiding in plain sight for years. During the diabetes trials, doctors kept noticing that patients were losing significant weight. In 2014, the FDA approved a higher-dose version — 3.0 mg, marketed as Saxenda — specifically for weight management. In clinical trials, patients lost an average of 8% of their body weight. For the first time, doctors had a safe, effective prescription tool for obesity that actually worked.

    Liraglutide opened the floodgates. It proved that GLP-1 drugs could treat both diabetes and obesity, paving the way for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). In 2024, the three pioneers — Habener, Mojsov, and Knudsen — received the prestigious Lasker Award, often called 'America's Nobel Prize,' for their work creating a new class of medicines that is transforming global health.

    The anglerfish hormone that nobody believed in had become the most important drug class of the 21st century.

15 milestones, 1902 – 2024.

  1. 1902Bayliss and Starling discover secretin — the first known hormone from the gut
  2. 1932La Barre coins the term 'incretin' for gut hormones that stimulate insulin
  3. 1964Scientists confirm the 'incretin effect' — oral sugar triggers more insulin than IV sugar
  4. 1983Habener's team discovers GLP-1 gene hidden inside glucagon while studying anglerfish
  5. 1986Mojsov and Habener show GLP-1 is produced in the intestine, not just the pancreas
  6. 1987Landmark paper proves GLP-1(7-37) powerfully stimulates insulin — the incretin is found
  7. 1992Holst proves GLP-1 still works in type 2 diabetes patients, unlike the similar hormone GIP
  8. 1997Knudsen's team at Novo Nordisk identifies liraglutide using the fatty acid trick
  9. 2000First human clinical trials of liraglutide begin
  10. 2007LEAD clinical trial program launches — the largest GLP-1 study at that time
  11. 2009European Medicines Agency approves Victoza for type 2 diabetes
  12. 2010FDA approves Victoza (liraglutide 1.8 mg) for type 2 diabetes in the United States
  13. 2014FDA approves Saxenda (liraglutide 3.0 mg) for chronic weight management
  14. 2016LEADER trial shows liraglutide reduces cardiovascular death by 13%
  15. 2024Habener, Mojsov, and Knudsen win the Lasker Award for GLP-1 drug development

Imagine your gut has a built-in appetite remote control. Every time you eat, your intestines release a tiny chemical messenger called GLP-1 that tells your brain 'you're full' and tells your pancreas 'make more insulin.' Liraglutide is a souped-up copy of that messenger — one that lasts all day instead of disappearing in two minutes.

Molecular structure

Amino Acids
31
Molecular Weight
3,751 Da
Half-life
~13 hours
Homology to GLP-1
97%
Formula
C₁₇₂H₂₆₅N₄₃O₅₁
Albumin Binding
99%

9M+Patients Treated Worldwide

Since 2010

8%Average Weight Loss

With Saxenda over 56 weeks

13%Heart Risk Reduction

LEADER trial results

100+Countries with Access

Victoza and Saxenda combined

Real stories, real lives

  • Maria Gonzalez

    I'd tried everything — diets, exercise programs, three different diabetes pills. My blood sugar was still out of control and I kept gaining weight. My doctor started me on Victoza, and within three months, my blood sugar numbers were the best they'd been in years. I lost 15 pounds without even trying. For the first time, I felt like my body was working with me instead of against me.
  • James Park

    At 310 pounds, I was pre-diabetic with high blood pressure. I'd lost and regained hundreds of pounds over the years. Saxenda was different. It was like someone finally turned down the volume on my hunger. I wasn't constantly thinking about food anymore. Over a year, I lost 45 pounds and my pre-diabetes reversed completely. My doctor said it was like watching someone get younger.

The future of Liraglutide

  • Next-Generation GLP-1 DrugsApproved / Phase 3

    Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) build on liraglutide's foundation with even longer action and greater weight loss

  • Oral GLP-1 PillsApproved 2019

    Oral semaglutide (Rybelsus) proved that GLP-1 drugs don't have to be injections — a pill form was once thought impossible

  • Triple-Hormone CombinationsPhase 2-3 Trials

    New drugs combining GLP-1 with two other gut hormones (GIP and glucagon) for even more powerful effects on weight and blood sugar

  • Beyond Diabetes and ObesityClinical Trials

    GLP-1 drugs are being tested for heart failure, kidney disease, liver disease, Alzheimer's, and addiction — the benefits may reach far beyond weight loss

Be inspired

The story of Liraglutide is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Liraglutide Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.